Home » KemPharm Receives Complete Response Letter for Acute Pain Candidate
KemPharm Receives Complete Response Letter for Acute Pain Candidate
The FDA has rejected KemPharm’s application for its abuse-deterrent, short-term acute pain management candidate Apadaz.
Company President and CEO Travis Mickle said the clinical-stage drugmaker is evaluating the points raised in the agency’s complete response letter and that it intends to request a meeting with the agency to determine the next steps.
Company spokesman Jim Heins declined further comment.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May